A Three-part, Randomized Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy, Young Subjects and Elderly Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs BC 007 (Primary)
- Indications Dilated cardiomyopathy
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Berlin Cures
- 21 Jun 2017 Study has changed from part two to part three,and dose of drug has also changed,hence patient number has also changed from 44 to74.
- 14 Jun 2017 Planned number of patients changed from 44 to 74.
- 14 Jun 2017 Planned End Date changed from 1 Jan 2017 to 1 Dec 2017.